Movahedi Bahram, Mokarram Pooneh, Hemmati Mina, Mosavari Nader, Zare Razie, Ardekani Leila Safaee, Mostafavi-Pour Zohreh
Recombinant Protein Laboratory, Department of Biochemistry, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Gastroenterohepatology Research Center, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Iran J Med Sci. 2017 May;42(3):275-283.
Discriminating latent tuberculosis infection (LTBI) from active TBI may be challenging. The objective of this study was to produce the recombinant L-alanine dehydrogenase (AlaDH) antigen and evaluate individuals with LTBI, those with active TBI, and uninfected individuals by enzyme-linked immunospot assay (ELISPOT) in order to distinguish LTBI from active TBI.
This exploratory study was performed in the Iranian city of Shiraz from 2014 to 2015. The study population (N=99) was divided into 3 groups: individuals with newly diagnosed active TBI (n=33), their household contacts (n=33), and controls (n=33). AlaDH was produced through PCR and cloning methods. The diagnostic characteristics of AlaDH vs. ESAT-6/CFP-10 were evaluated in responses to interferon-γ (IFN-γ) and interleukin-2 (IL-2) with ELISPOT. Differences between the groups were assessed with the Kruskal-Wallis and Mann-Whitney tests for nonparametric data analysis. The statistical analyses were performed with SPSS, version 16.
IFN-γ responses to both ESAT-6/CFP-10 (P=0.81) and AlaDH (P=0.18) revealed that there were no significant differences between the individuals with LTBI and those with active TBI. The same results were determined for IL-2 responses to ESAT-6/CFP-10 between the 2 groups, while significantly higher IL-2 responses to AlaDH were observed in LTBI than in active TBI. According to the ROC curve analysis, a cutoff value of 275 SFC showed sensitivity of 75.8% and specificity of 78.8% for distinguishing LTBI from active TBI by IL-2 responses to AlaDH.
The current study suggests that it may be possible to discriminate LTBI from active TBI by IL-2 responses to AlaDH.
区分潜伏性结核感染(LTBI)和活动性结核病(TBI)可能具有挑战性。本研究的目的是制备重组L-丙氨酸脱氢酶(AlaDH)抗原,并通过酶联免疫斑点试验(ELISPOT)对LTBI患者、活动性TBI患者和未感染个体进行评估,以区分LTBI和活动性TBI。
这项探索性研究于2014年至2015年在伊朗设拉子市进行。研究人群(N = 99)分为3组:新诊断为活动性TBI的个体(n = 33)、其家庭接触者(n = 33)和对照组(n = 33)。通过PCR和克隆方法制备AlaDH。使用ELISPOT评估AlaDH与ESAT-6/CFP-10在干扰素-γ(IFN-γ)和白细胞介素-2(IL-2)反应中的诊断特征。使用Kruskal-Wallis检验和Mann-Whitney检验对非参数数据分析评估组间差异。使用SPSS 16版进行统计分析。
IFN-γ对ESAT-6/CFP-10(P = 0.81)和AlaDH(P = 0.18)的反应表明,LTBI患者和活动性TBI患者之间无显著差异。两组间ESAT-6/CFP-10的IL-2反应结果相同,而LTBI患者对AlaDH的IL-2反应显著高于活动性TBI患者。根据ROC曲线分析,275个斑点形成细胞(SFC)的临界值在通过AlaDH的IL-2反应区分LTBI和活动性TBI时显示出75.8%的敏感性和78.8%的特异性。
本研究表明,通过对AlaDH的IL-2反应可能区分LTBI和活动性TBI。